"I am thrilled to bring VBrain to our partners across the U.S. and Taiwan," says Jen-Tang Lu, CEO of Vysioneer. "Receiving unique FDA clearance for this solution allows Vysioneer to further its commitment of transforming radiotherapy workflows through developing full body auto-contouring solutions. The future of AI is near, bringing a second set of eyes and hands to assist clinicians in analyzing and segmenting medical scans and further improving patient cancer care."
About Vysioneer
Vysioneer is a leading Artificial Intelligence solution provider aiming to pioneer transformation in cancer care using cutting edge innovation. Vysioneer leverages its proprietary deep learning technology to augment clinicians' productivity and deliver precision medicine for better patient outcomes. The company's featured product, VBrain, is a first-ever FDA-cleared tumor auto-contouring system that optimizes brain tumor radiosurgery with enhanced precision and efficiency. Vysioneer is headquartered in Boston with an office in Taipei, Taiwan.
SOURCE Vysioneer, Inc.
Back to HCB News